Key data from Merck’s portfolio and pipeline to be presented at the 2026 ASCO GU Cancers Symposium: First-time data from the Phase 3 KEYNOTE-B15/EV-304 trial evaluating KEYTRUDA, Merck’s… read more.
Biofrontera Inc. announced that the FDA has completed its filing review and accepted filing of the Company’s supplemental New Drug Application (sNDA) for Ameluz (aminolevulinic acid hydrochloride) topical… read more.
Ono Pharmaceutical Co., Ltd. announced that the FDA has accepted for filing the New Drug Application (NDA) under the accelerated approval pathway for tirabrutinib, a highly selective irreversible,… read more.
In the U.S., one in eight women will get breast cancer in their lifetime, and about half of them will have mastectomies. Many of those women opt to… read more.
Pfizer Inc. announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating Braftovi (encorafenib) in combination with cetuximab (Erbitux) and FOLFIRI (fluorouracil,… read more.
How to reduce suffering in children with advanced cancer remains an ongoing but urgent question. A Mass General Brigham-led study examined whether systematically surveying children with advanced cancer… read more.
NICE (UK): Avelumab plus axitinib can be used as an option for untreated advanced renal cell carcinoma (RCC) in adults, only if: i) they have a favourable-risk status,… read more.
People with compromised liver function may be able to reduce their risk of liver cancer or slow its progression with a simple dietary change: eating less protein. A… read more.
Gilead Sciences Inc. announced Trodelvy (sacituzumab govitecan-hziy) has now been added to the NCCN Guidelines as a category 1 preferred first-line treatment option for people with metastatic triple-negative… read more.
A new AI-powered model has been shown to advance treatment planning for spinal metastasis by calculating patients’ chances of survival. Doctors can then make informed decisions about, for… read more.
The long term use of proton pump inhibitors (PPIs), a class of drugs widely used to treat acid reflux and ulcers, may not be linked to any increased… read more.
Telix Pharmaceuticals Limited announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has accepted the filing of a New Drug Application (NDA) for… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
